

International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 68 Proposed INN not later than 30 June 1993**.

Proposed International Nonproprietary Names: List 68


Lists of proposed (1–65) and recommended (1–31) international nonproprietary names can be found in Cumulative List No. 8, 1992.

Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

alestramustinum
alestramustine

estradiol 3-[bis(2-chloroethyl)carbamate], 17-ester with L-alanine
 $C_{26}H_{36}Cl_2N_2O_4$ 139402-18-9 *antineoplastic*



alglucerasum
alglucerase

glucosylceramidase (human placenta isoenzyme protein moiety reduced)
 $C_{2532}H_{3854}N_{672}O_{711}S_{16}$ 143003-46-7 *glucocerebrosidase*
(for non-glycosylated protein)


***Action and Use:** *The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

alovudinum
alovudine

3'-deoxy-3'-fluorothymidine
 $C_{10}H_{13}FN_2O_4$ 25526-93-6 *antiviral*



altumomabum
aitumomab


immunoglobulin G 1 (mouse monoclonal ZCE025 anti-human antigen CEA),
disulfide with mouse monoclonal ZCE025 light chain, dimer
radiodiagnostic monoclonal antibody

ardeparinum natricum
ardeparin sodium

Sodium salt of depolymerized heparin obtained by peroxide degradation (at elevated temperature) of heparin from pork intestinal mucosa: the end chain structure appears to be the same as the starting material with no unusual sugar residues present; the low molecular weight heparin produced differs from the starting material in molecular weight only; the average relative molecular mass range is 5,500 to 6,500 daltons, 98 per cent of which ranging between 2,000 and 15,000; the degree of sulfation is approximately 2.7 per disaccharidic unit.
anticoagulant

atrinositolum
atrinositol

D-myo-inositol 1,2,6-tris(dihydrogen phosphate)
 $C_6H_{15}O_{15}P_3$ 28841-62-5 *neuropeptide antagonist*




avicationinum
avicationin

1-butyrac acid-2-L-alanine-3-L-serine-7-(L-2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alaninecalcitonin (salmon)
 $C_{147}H_{243}N_{41}O_{46}$ 103451-84-9 *calcium regulator*

azasetronum
azasetron

(±)-6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide
 $C_{17}H_{20}ClN_3O_3$ 123040-69-7 *serotonin receptor antagonist*




Proposed International
Nonproprietary Name
(Latin. English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


berefirinum
berefirine

m-[(2*R*,5*R*)-2-*tert*-butyl-3-methyl-5-oxazolidinyl]phenol mixture with *m*-[(2*S*,5*R*)-2-*tert*-butyl-3-methyl-5-oxazolidinyl]phenol
 $C_{14}H_{21}NO_2$ 105567-83-7 *mydriatic*




besigomsinum
besigomsin

(+)-(6*S*,7*S*, *bis*-*R*)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-*f*][1,3]benzodioxol-6-ol
 $C_{29}H_{28}O_7$ 58546-54-6 *hepatoprotectant*




bizelesinum
bizelesin

1,3-bis[2-[(*S*)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-*b*.4.3-*b'*]dipyrrol-3(2*H*)-yl]carbonyl]indol-5-yl]urea
 $C_{49}H_{36}Cl_2N_8O_8$ 129655-21-6 *antineoplastic*




cefcapeum
cefcape

(6*R*,7*R*)-7-[(*Z*)-2-(2-amino-4-thiazolyl)-2-pentenamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, carbamate (ester)
 $C_{17}H_{19}N_5O_6S_2$ 135889-00-8 *antibiotic*



cetefloxacinum
cetefloxacin

(-)-7-[(2*S*,3*R*)-3-amino-2-methyl-1-azetidiny]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
 $C_{20}H_{16}F_3N_3O_3$ 141725-88-4 *antibacterial*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


clansetronum
clansetron

(-)-(R)-5,6,9,10-tetrahydro-10-[[2-methylimidazol-1-yl)methyl]-4H-pyrido[3,2,1-*jk*]carbazol-11(8*H*)-one
 $C_{20}H_{21}N_3O$ 120635-74-7 serotonin receptor antagonist




cladribinum
cladribine

2-chloro-2'-deoxyadenosine
 $C_{10}H_{12}ClN_5O_3$ 4291-63-8 antileukaemic




clinprostum
clinprost

(+)-methyl (3*aS*,5*R*,6*R*,6*aS*)-1,3*a*,4,5,6,6*a*-hexahydro-5-hydroxy-6-[(*E*)-(3*S*)-3-hydroxy-1-octenyl]-2-pentalevalerate
 $C_{22}H_{36}O_4$ 88931-51-5 platelet aggregation inhibitor




dezinamidum
dezinamide

3-[(α,α,α -trifluoro-*m*-tolyl)oxy]-1-azetidinecarboxamide
 $C_{11}H_{11}F_3N_2O_2$ 91077-32-6 anticonvulsant




dimiracetamum
dimiracetam

(\pm)-dihydro-1*H*-pyrrolo[1,2-*a*]imidazole-2,5(3*H*,6*H*)-dione
 $C_6H_8N_2O_2$ 126100-97-8 nootropic



duloxetineum
duloxetine

(+)-(S)-*N*-methyl- γ -(1-naphthyl)-2-thiophenepropylamine
 $C_{18}H_{19}NOS$ 116539-59-4 antidepressant




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


ecadotrilum
ecadotril

N-[(*S*)- α -(mercaptomethyl)hydrocinnamoyl]glycine, benzyl ester, acetate (ester)
 $C_{21}H_{23}NO_4S$ 112573-73-6 *endopeptidase inhibitor*




enadolinum
enadoline
()

N-methyl-*N*-[(5*R*,7*S*,8*S*)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-4-benzofuranacetamide
 $C_{24}H_{32}N_2O_3$ 124378-77-4 *analgesic*




enazadremum
enazadrem

4,6-dimethyl-2-[(6-phenylhexyl)amino]-5-pyrimidinol
 $C_{18}H_{25}N_3O$ 107361-33-1 *antipsoriatic*



fialuridinum
fialuridine

1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-5-iodouracil
 $C_9H_{10}FIN_2O_5$ 69123-98-4 *antiviral*



Proposed International
Nonproprietary* Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

ganefromycinum
ganefromycin

An antibiotic produced by *Streptomyces lydicus*
Ganefromycin is a complex antibiotic with two major components: α and β .

component α



(2*E*,4*E*,6*E*)-7-[(2*R**,3*R**,5*R**)-5-[7-[(3*E*,5*E*)-3-[[*O*-2,6-dideoxy-3-*O*-methyl- α -lyxo-hexopyranosyl-(1 \rightarrow 4)-*O*-2,6-dideoxy-3-*O*-methyl- β -ribo-hexopyranosyl-(1 \rightarrow 4)-2,6-dideoxy-3-*O*-methyl- α -lyxo-hexopyranosyl]oxy]-2-[(2*S**,3*S**,4*S**,6*R**)-tetrahydro-2,3,4-trihydroxy-5,5-dimethyl-6-[(1*E*,3*Z*)-1,3-pentadienyl]-2*H*-pyran-2-yl]propionamido]-2-methoxy-1,3-dimethyl-3,5-heptadienyl]tetrahydro-3-hydroxy-2-furyl]-2,4,6-heptatrienoic acid, 2³-phenylacetate
114451-31-9

component β

(2*E*,4*E*,6*E*)-7-[(2*R**,3*R**,5*R**)-5-[7-[(3*E*,5*E*)-3-[[*O*-2,6-dideoxy-3-*O*-methyl- α -lyxo-hexopyranosyl-(1 \rightarrow 4)-*O*-2,6-dideoxy-3-*O*-methyl- β -ribo-hexopyranosyl-(1 \rightarrow 4)-2,6-dideoxy-3-*O*-methyl- α -lyxo-hexopyranosyl]oxy]-2-[(2*S**,3*S**,4*S**,6*R**)-tetrahydro-2,3,4-trihydroxy-5,5-dimethyl-6-[(1*E*,3*Z*)-1,3-pentadienyl]-2*H*-pyran-2-yl]propionamido]-2-methoxy-1,3-dimethyl-3,5-heptadienyl]tetrahydro-3-hydroxy-2-furyl]-2,4,6-heptatrienoic acid, 2⁴-phenylacetate
114451-30-8


C₆₅H₉₅NO₂₁ (empirical molecular formula)

growth stimulant,
antibacterial (vet.)




glemanserinum
glemanserin

(\pm)-1-phenethyl- α -phenyl-4-piperidinemethanol
C₂₀H₂₅NO 107703-78-6 serotonin receptor antagonist



grepafloxacinum
grepafloxacin

(\pm)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
C₁₉H₂₂FN₃O₃ 119914-60-2 antibacterial




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description. Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


gusperimus
gusperimus

(±)-N-[[[4-[(3-aminopropyl)amino]butyl]carbonyl]hydroxymethyl]-7-guanidinoheptanamide
 $C_{17}H_{37}N_7O_3$ 104317-84-2 immunosuppressant




icodextrinum
icodextrin

dextrin, having more than 85% of its molecules with molecular masses between 1640 and 45000 with a claimed-average molecular mass of approximately 20000
 $[C_6H_{12}O_6]_n$ 9004-53-9 peritoneal dialysis fluid




icoduline
icodulinum

6-(2-thiazolylamino)-*m*-cresol
 $C_{10}H_{10}N_2OS$ 138511-81-6 non steroidal anti-inflammatory




idoxifenum
idoxifene

1-[2-[*p*-[(*E*-β-ethyl-α-(*p*-iodophenyl)styryl]phenoxy]ethyl]pyrrolidine
 $C_{28}H_{30}INO$ 116057-75-1 antineoplastic



igmesinum
igmesine

(+)-α-[(*E*-cinnamyl)-*N*-(cyclopropylmethyl)-α-ethyl-*N*-methylbenzylamine
 $C_{23}H_{29}N$ 140850-73-3 σ opiate receptor antagonist




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


iobitridolum
iobitridol

N,N'-bis(2,3-dihydroxypropyl)-5-[2-(hydroxymethyl)hydracrylamido]-2,4,6-triodo-*N,N'*-dimethylisophthalamide
 $C_{20}H_{28}I_3N_3O_9$ 136949-58-1 *contrast medium*




itasetronum
itasetron

2-oxo-*N*-1 α ,5 α -*H*-tropan-3 α -yl-1-benzimidazole-1-carboxamide
 $C_{16}H_{20}N_4O_2$ 123258-84-4 *serotonin receptor antagonist*




leminoprazolum
leminoprazole

(\pm)-2-[[*o*-(isobutylmethylamino)benzyl]sulfinyl]benzimidazole
 $C_{19}H_{23}N_3OS$ 104340-86-5 *antiulcer*




levosimendanum
levosimendan

mesoxalonitrile (–)-[*p*[(*R*)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone
 $C_{14}H_{12}N_6O$ 141505-33-1 *cardiac stimulant*



lomerizinum
lomerizine

1-[bis(*p*-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine
 $C_{27}H_{30}F_2N_2O_3$ 101477-55-8 *cerebral vasodilator*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


losoxantrone
losoxantrone

7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthra[1,9-*cd*]pyrazol-6(2*H*)-one
 $C_{22}H_{27}N_5O_4$ 88303-60-0 *antineoplastic*



monatepilum
monatepil

(±)-*N*-(6,11-dihydrodibenzo[*b,e*]thiepin-11-yl)-4-(*p*-fluorophenyl)-1-piperazinebutyramide
 $C_{28}H_{30}FN_3OS$ 132019-54-6 *calcium channel blocker*




nasaruplasum
nasaruplase

prouokinase (enzyme-activating) (human clone pA3/pD2/pF1 protein moiety)
 $C_{2031}H_{3121}N_{585}O_{601}S_{31}$ 99821-44-0 *enzyme*


niravolinum
niravoline

N-methyl-2-(*m*-nitrophenyl)-*N*-[(1*S*,2*S*)-2-(1-pyrrolidinyl)-1-indanyl]acetamide
 $C_{22}H_{25}N_3O_3$ 130610-93-4 *diuretic*




odapipamum
odapipam

(+)-(S)-8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-1*H*-3-benzazepin-7-ol
 $C_{19}H_{20}ClNO_2$ 131796-63-9 *dopamine D₁ receptor antagonist*



orbifloxacinum
orbifloxacin

1-cyclopropyl-7-(*cis*-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
 $C_{19}H_{20}F_3N_3O_3$ 113617-63-3 *antibacterial*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


osateronum
osaterone

(+)-6-chloro-17-hydroxy-2-oxapregna-4,6-diene-3,20-dione
 $C_{20}H_{25}ClO_4$ 105149-04-0 *antiandrogen, progestogen*




paclitaxelum
paclitaxel

(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-benzoyl-3-phenylisoserine
 $C_{47}H_{61}NO_4$ 33069-62-4 *antineoplastic*




pidobenzonum
pidobenzone

5-oxo-L-proline, *p*-hydroxyphenyl ester
 $C_{11}H_{11}NO_4$ 138506-45-3 *melanine synthesis inhibitor*



ramorelixum
ramorelix

1-[*N*-acetyl-3-(2-naphthyl)-*D*-alanyl-*p*-chloro-*D*-phenylalanyl-*D*-tryptophyl-L-seryl-L-tyrosyl-*O*-(6-deoxy- α -L-mannopyranosyl)-*D*-seryl-L-leucyl-L-arginyl-L-prolyl]semicarbazide
 $C_{74}H_{95}ClN_{16}O_{18}$ 136639-71-9 *lutening-hormone-releasing-hormone inhibitor*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


raxofelastum
raxofelast

(±)-2,3-dihydro-5-hydroxy-4,6,7-trimethyl-2-benzofuranacetic acid, acetate
C₁₅H₁₈O₅ 128232-14-4 *antialsthmatic, anti-inflammatory*




safironilum
safironil

N,N'-bis(3-methoxypropyl)-2,4-pyridinedicarboxamide
C₁₅H₂₃N₃O₄ 134377-69-8 *collagen inhibitor*




sameridinum
sameridine

N-ethyl-1-hexyl-*N*-methyl-4-phenylisonipecotamide
C₂₁H₃₄N₂O 143257-97-0 *analgesic, local anaesthetic*




sanguinarin chloridum
sanguinarium chloride

sanguinarine chloride *or* 13-methyl[1,3]benzodioxolo[5,6-*c*]-1,3-dioxolo[4,5-*i*]=phenanthridinium chloride
C₂₀H₁₄ClNO₄ 5578-73-4 *anti-inflammatory; antimicrobial; antifungal*




carboplatinum
carboplatin

(+)-*cis*-(1,1-cyclobutanedicarboxylato)[(2*R*)-2-methyl-1,4-butanediamine-*N,N'*]platinum
C₁₁H₂₀N₂O₄Pt 110172-45-7 *antineoplastic*



sepi-mostatum
sepi-mostat

6-amidino-2-naphthyl *p*-(2-imidazolin-2-ylamino)benzoate
C₂₁H₁₅N₅O₂ 103926-64-3 *protease inhibitor*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

siratiazemum
siratiazem

(+)-(2*S*,3*S*)-2,3-dihydro-3-hydroxy-5-[2-(isopropylmethylamino)ethyl]-2-(*p*-methoxyphenyl)-1.5-benzothiazepin-4(5*H*)-one acetate (ester)
 $C_{24}H_{30}N_2O_4S$ 138778-28-6 *antianginal, antihypertensive*




sonerminum
sonermin

3-157-tumor necrosis factor (human)
 $C_{767}H_{1204}N_{210}O_{229}S_2$ 144916-42-7 *antineoplastic*


sulopenemum
sulopenem

(5*R*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-7-oxo-3-[[3(*S*)-tetrahydro-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (*R*)-*S*-oxide
 $C_{12}H_{15}NO_5S_3$ 120788-07-0 *antibacterial*




tallimustinum
tallimustine

N'-(2-amidinoethyl)-4-[*p*-[bis(2-chloroethyl)amino]benzamido]-1,1',1''-trimethyl-*N*,4',*N*',4''-ter[pyrrole-2-carboxamide]
 $C_{32}H_{38}Cl_2N_{10}O_4$ 115308-98-0 *antineoplastic*



tarazepidum
tarazepide

(-)-*N*-[(*S*)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoline-2-carboxamide
 $C_{28}H_{24}N_4O_2$ 141374-81-4 *cholecystokinin inhibitor*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


teloxantrone
teloxantrone

7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino)ethyl]amino]anthra[1,9-*cd*]pyrazol-6(2*H*)-one
 $C_{21}H_{25}N_5O_4$ 91441-48-4 *antineoplastic*




thymoctonanum
thymoctonan

N-[*N*-[1-[*N*-[*N*-(*N*-L-leucyl-L- α -glutamyl)-L- α -aspartyl]glycyl]-L-prolyl]-L-lysyl]-L-phenylalanyl]-L-leucine
 $C_{43}H_{87}N_9O_{13}$ 107489-37-2 *immunomodulator*




tiquesidum
tiqueside

(25*R*)-5 α -spirostan-3 β -yl 4-*O*- β -D-glucopyranosyl- β -D-glucopyranoside
 $C_{39}H_{64}O_{13}$ 99759-19-0 *antihyperlipidaemic*



tirapazaminum
tirapazamine

3-amino-1,2,4-benzotriazine 1,4-dioxide
 $C_7H_6N_4O_2$ 27314-97-2 *antineoplastic*




Proposed International
Nonproprietary Name
(Latin, English)*

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


troglitazonum
troglitazone

(±)-all-rac-5-[p-[(6-hydroxy-2,5,7,8-tetramethyl-2-chroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione
C₂₄H₂₇NO₅S 97322-87-7 hypoglycaemic

1:1 mixture of




with




valsartanum
valsartan

N-[p-(o-1H-tetrazol-5-yl)phenyl]benzyl]-N-valeryl-L-valine
C₂₄H₂₉N₅O₃ 137862-53-4 antihypertensive



zamiifenacinum
zamiifenacin

(R)-3-(diphenylmethoxy)-1-[3,4-(methylenedioxy)phenethyl]piperidine
C₂₇H₂₉NO₃ 127308-82-1 muscarin receptor antagonist



AMENDMENTS TO PREVIOUS LISTS

Chronicle of the World Health Organization Vol. 7, No. 10, 1953

Proposed International Nonproprietary Names (Prop. INN): List 1

p. 304	<i>delete</i>	<i>insert</i>
	corticotrophinum	corticotropinum
	corticotrophin	corticotropin

Chronicle of the World Health Organization Vol. 12, No. 3, 1958

Proposed International Nonproprietary Names (Prop. INN): List 6

p. 103	<i>delete</i>	<i>insert</i>
	corticotrophinum zinci	corticotropinum zinci
	hydroxydum	hydroxydum
	corticotrophin zinc hydroxide	corticotropin zinc hydroxide

Supplement to WHO Chronicle Vol. 37, No. 5, 1983

Proposed International Nonproprietary Names (Prop. INN): List 50

p. 14	icospiramidum icospiramide	<i>replace the chemical name by the following.</i> 8-[<i>cis</i> -4-cyano-4-(<i>p</i> -fluorophenyl)cyclohexyl]-1-(<i>p</i> -fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-3-acetamide
-------	-------------------------------	---

WHO Drug Information, Vol. 4, No. 2, 1990


Proposed International Nonproprietary Names (Prop. INN): List 63

p. 4	<i>delete</i>	<i>insert</i>
	docetaxolum	docetaxelum
	docetaxol	docetaxel

WHO Drug Information, Vol. 4, No. 4, 1990

Proposed International Nonproprietary Names (Prop. INN): List 64

p. 13	leuciglumerum leuciglumer	<i>replace the molecular formula and the graphic formula by the following:</i> (C ₆ H ₁₃ NO ₂ · C ₆ H ₁₁ NO ₄) _n
-------	------------------------------	---



Proposed International Nonproprietary Names (Prop. INN): List 66

- | | | |
|------|-----------------------------------|---|
| p. 4 | dexfosfoferinum
dexfosfoferine | <i>replace the chemical name by the following:</i>
(+)-L-serine dihydrogen phosphate (ester) |
| p. 6 | ilatreatidum
ilatreatide | <i>include the following CAS registry number:</i>
119719-11-8 |

Proposed International Nonproprietary Names (Prop. INN): List 67

- | | | |
|-------|--------------------------|---|
| p. 9 | satumomabum
satumomab | <i>include the following CAS registry number:</i>
144058-40-2 |
| p. 12 | limaprostum
limaprost | <i>replace the chemical name by the following:</i>
(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid |

Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only